Earnings Flash (NVCR) NOVOCURE Posts Q1 Revenue $137.5M, vs. Street Est of $134.3M
© MT Newswires 2022
| All news about NOVOCURE LIMITED |
|
| 06/21 | NovoCure Enrolls First Patient in Study of Tumor Treating Fields, Keytruda Combination .. | MT |
| 06/21 | Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields T.. | BU |
| 06/21 | Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields T.. | CI |
| 06/10 | NOVOCURE LTD : Change in Directors or Principal Officers, Amendments to Articles of Inc. o.. | AQ |
| 06/06 | HC Wainwright Initiates NovoCure at Buy, Sets Price Target at $115 | MT |
| 06/03 | Novocure Falls 5%, Zai Lab Rises 8%; Companies Report Study Results | DJ |
| 06/03 | Zai Lab, Novocure's Phase 2 Study of Gastric Cancer Combination Therapy Meets Primary E.. | MT |
| 06/03 | NOVOCURE : Press Release of NovoCure Limited, dated June 3, 2022 - Form 8-K | PU |
| 06/03 | NOVOCURE LTD : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) | AQ |
| 06/03 | Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Field.. | BU |
| |
|
| Analyst Recommendations on NOVOCURE LIMITED |
|
| |
|
|
|
| Sales 2022 |
552 M
-
-
|
| Net income 2022 |
-62,6 M
-
-
|
| Net Debt 2022 |
293 M
-
-
|
| P/E ratio 2022 |
-130x |
| Yield 2022 |
- |
|
| Capitalization |
7 907 M
7 907 M
-
|
| EV / Sales 2022 |
14,9x |
| EV / Sales 2023 |
13,8x |
| Nbr of Employees |
1 167 |
| Free-Float |
86,5% |
|
|
|
|
Duration :
Period :
|
 | |
|
Technical analysis trends NOVOCURE LIMITED
| Short Term | Mid-Term | Long Term | | Trends | Neutral | Neutral | Bearish |
Income Statement Evolution
|
| Mean consensus |
OUTPERFORM |
| Number of Analysts |
9 |
| Last Close Price |
75,60 $ |
| Average target price |
101,44 $ |
| Spread / Average Target |
34,2% |
|
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
